Rabies - Pipeline Review, H1 2018

  • ID: 4515995
  • Drug Pipelines
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cadila Healthcare Ltd
  • Celltrion Inc
  • Curevac AG
  • Indian Immunologicals Ltd
  • NanoViricides Inc
  • PaxVax Inc
  • MORE
Rabies - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H1 2018, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Rabies - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 4, 2, 1, 15, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cadila Healthcare Ltd
  • Celltrion Inc
  • Curevac AG
  • Indian Immunologicals Ltd
  • NanoViricides Inc
  • PaxVax Inc
  • MORE
Introduction

Report Coverage

Rabies - Overview

Rabies - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rabies - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rabies - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Cadila Healthcare Ltd

Celltrion Inc

Curevac AG

Indian Immunologicals Ltd

Molecular Targeting Technologies Inc

NanoViricides Inc

PaxVax Inc

Prosetta Biosciences Inc

Sanofi Pasteur SA

Synermore Biologics Co Ltd

Trellis Bioscience Inc

VBI Vaccines Inc

Rabies - Drug Profiles

(Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNSP-333S1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-19 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-7202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-8102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMT-504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAb-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Glycoprotein for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nadorameran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAV-866 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RabiCide-I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rabimabs - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RabiVir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVC-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVC-58 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOJB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VerorabVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YSON-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rabies - Dormant Projects

Rabies - Product Development Milestones

Featured News & Press Releases

Jul 26, 2017: CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference

Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine

Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant

Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies

Aug 12, 2010: Zydus Joins WHO To Develop MAb Cocktail For Rabies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rabies, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Rabies - Pipeline by Cadila Healthcare Ltd, H1 2018

Rabies - Pipeline by Celltrion Inc, H1 2018

Rabies - Pipeline by Curevac AG, H1 2018

Rabies - Pipeline by Indian Immunologicals Ltd, H1 2018

Rabies - Pipeline by Molecular Targeting Technologies Inc, H1 2018

Rabies - Pipeline by NanoViricides Inc, H1 2018

Rabies - Pipeline by PaxVax Inc, H1 2018

Rabies - Pipeline by Prosetta Biosciences Inc, H1 2018

Rabies - Pipeline by Sanofi Pasteur SA, H1 2018

Rabies - Pipeline by Synermore Biologics Co Ltd, H1 2018

Rabies - Pipeline by Trellis Bioscience Inc, H1 2018

Rabies - Pipeline by VBI Vaccines Inc, H1 2018

Rabies - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Rabies, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Cadila Healthcare Ltd
  • Celltrion Inc
  • Curevac AG
  • Indian Immunologicals Ltd
  • Molecular Targeting Technologies Inc
  • NanoViricides Inc
  • PaxVax Inc
  • Prosetta Biosciences Inc
  • Sanofi Pasteur SA
  • Synermore Biologics Co Ltd
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll